NO20081233L - Albumin fusjonsproteiner - Google Patents

Albumin fusjonsproteiner

Info

Publication number
NO20081233L
NO20081233L NO20081233A NO20081233A NO20081233L NO 20081233 L NO20081233 L NO 20081233L NO 20081233 A NO20081233 A NO 20081233A NO 20081233 A NO20081233 A NO 20081233A NO 20081233 L NO20081233 L NO 20081233L
Authority
NO
Norway
Prior art keywords
albumin infusion
proteins
nucleic acids
vectors
fusion proteins
Prior art date
Application number
NO20081233A
Other languages
English (en)
Inventor
Adam Bell
Yanggu Shi
David Lafleur
Craig Rosen
Paul Moore
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO20081233L publication Critical patent/NO20081233L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse omfatter albuminfusjonsproteinet. Nukleinsyremolekylene kodende for albuminfusjonsproteinene av oppfinnelsen er også omsluttet av oppfinnelsen, det er er også vektorer inneholdende disse nukleinsyrene, vertsceller transformert med disse nukleinsyrevektorene og fremgangsmåter for å lage albuminfusjonsproteiner ifølge oppfinnelsen, og å benytte disse nukleinsyrene, vektorene og/eller vertscellene. I tillegg omslutter den foreliggende oppfinnelsen farmasøytiske sammensetninger omfattende albuminfusjonsproteiner og deres fremgangsmåter og behandling, forebygging eller forbedring av sykdommer, lidelser eller tilstander ved å benytte albuminfusjonsproteiner av oppfinnelsen.
NO20081233A 2005-08-12 2008-03-10 Albumin fusjonsproteiner NO20081233L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
NO20081233L true NO20081233L (no) 2008-05-09

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081233A NO20081233L (no) 2005-08-12 2008-03-10 Albumin fusjonsproteiner

Country Status (13)

Country Link
EP (1) EP1924596A4 (no)
JP (1) JP2009504157A (no)
KR (1) KR20080071119A (no)
AU (1) AU2006280312A1 (no)
BR (1) BRPI0614761A2 (no)
CA (1) CA2618476A1 (no)
EC (1) ECSP088262A (no)
IL (1) IL189246A0 (no)
MA (1) MA29836B1 (no)
MX (1) MX2008001865A (no)
NO (1) NO20081233L (no)
TN (1) TNSN08064A1 (no)
WO (1) WO2007021494A2 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0712383A2 (pt) 2006-06-07 2012-07-10 Human Genome Sciences Inc proteìnas de fusão da albumina
MX2009002816A (es) * 2006-09-14 2009-05-28 Human Genome Sciences Inc Proteinas de fusion de albumina.
EP2450368A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物
SG172940A1 (en) 2009-01-16 2011-08-29 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
CN106986933A (zh) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 白蛋白变体和缀合物
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
WO2011146902A1 (en) 2010-05-21 2011-11-24 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EP3189835B1 (en) * 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012954U1 (de) 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DK2583677T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
HUE046396T2 (hu) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc Kiméra faktor VIII polipeptidek és ezek alkalmazása
EA201491470A1 (ru) 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. Композиции фактора viii и способы получения и использования подобных
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测***
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
JP2016523919A (ja) 2013-06-28 2016-08-12 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4389139A2 (en) 2014-01-10 2024-06-26 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
MA50141A (fr) * 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
TW201946929A (zh) 2018-02-01 2019-12-16 美商生物化學醫療公司 表現因子ｖｉｉｉ之慢病毒載體之使用
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
KR20210042128A (ko) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
MX2021006648A (es) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor ix.
EP4038182A1 (en) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JPWO2022030580A1 (no) * 2020-08-06 2022-02-10
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5424521B2 (ja) * 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CA2554089C (en) * 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
EP1924596A4 (en) 2009-07-29
JP2009504157A (ja) 2009-02-05
ECSP088262A (es) 2008-05-30
AU2006280312A1 (en) 2007-02-22
KR20080071119A (ko) 2008-08-01
WO2007021494A3 (en) 2007-07-26
BRPI0614761A2 (pt) 2009-05-19
TNSN08064A1 (en) 2009-07-14
MX2008001865A (es) 2008-04-15
EP1924596A2 (en) 2008-05-28
IL189246A0 (en) 2008-08-07
CA2618476A1 (en) 2007-02-22
WO2007021494A2 (en) 2007-02-22
MA29836B1 (fr) 2008-10-03

Similar Documents

Publication Publication Date Title
NO20081233L (no) Albumin fusjonsproteiner
NO20064059L (no) Albumin fusjonsproteiner
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
EP1276756A1 (en) Albumin fusion proteins
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
WO2007092772A3 (en) Protein formulations
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK1888641T3 (da) Serumalbuminbindende proteiner
DK2369005T3 (da) Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
NO20052276D0 (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
DE602005024442D1 (de) Wiederherstellung der aktivität von 5-enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2008070586A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2008125280A3 (en) New modulating molecules for an improved regulated expression system

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application